Do you have opinion on what may have caused Anavex "Adapting" to MonoTherapy as lone target? No Anavex Plus? I am of the opinion we see convincing evidence of Monotherapy this week and that is why.. Do you think we will see any data from patients that switched from Dual To MonoTherapy? I just think the good Dr will have to explain with Data WHY AnavexPlus is no longer a target.
Yes, thank you. The Times They Are A-Changin'. However, most haven't gotten it yet. You did. Why wouldn't the FDA not favor the adaptive design if done correctly and more accurate it is more efficient and it makes the FDA's job easier? Additionally, more pressure is being exerted on the FDA to speed up its drug approval process -- witness the Cures Act. How can the FDA be more efficient in drug approvals if it clings to the old design?
News 
Market Data 
Discover 
